Janssen Pharmaceuticals Receives FDA Clearance for Nucynta ER

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has received approval from the Food and Drug Administration for a new supplemental drug for an opioid analgesic to treat pain related to diabetes.

Advertisement

Nucynta ER is approved to treat neuropathic pain associated with diabetic peripheral neuropathy in adult patients. It is the only opioid approved by the FDA for DPN-associated neuropathic pain.

More Articles on Pain Management:

10 Pain Management Physicians on the Move

ASIPP Releases Guidelines on Opioid Prescriptions for Non-Cancer Pain Patients

Kansas University Hospital Addition Includes Pain Management

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.